** Shares in Carl Zeiss Meditec AFXG.DE jump more than 6%
after the German medical technology group posted higher annual
revenue and gave a more optimistic outlook
** The company's FY 2022/23 revenue rises 9.8% to 2.09 bln
euros ($2.24 bln)
** It expects FY 2023/24 revenue growth to be at least as
high as market growth and EBIT to be roughly level with previous
year
** In the medium term, the company expects to stabilize EBIT
margin sustainably above 20%, while extensive investments will
also be continued
** A local trader says the 2023/24 outlook seems better than
the fears that emerged over the last weeks, and the medium-term
outlook is more optimistic than earlier this year
** "Should be enough for AFX shares to continue recent
uptrend," the trader says
** The stock is the top performer on Germany's mid-cap index
.MDAXI
($1 = 0.9279 euros)
(Reporting by Ozan Ergenay)
((ozan.ergenay@thomsonreuters.com))